A Clinical Trial to Assess the Effects of Ustekinumab and Etanercept on Skin and Blood Biomarkers of Psoriasis in Patients With Moderate to Severe Disease.
Phase of Trial: Phase I
Latest Information Update: 08 May 2014
At a glance
- Drugs Ustekinumab (Primary) ; Etanercept
- Indications Plaque psoriasis
- Focus Biomarker; Pharmacodynamics
- Sponsors Merck & Co
- 10 Jun 2017 Biomarkers information updated
- 17 Jan 2012 Actual end date (December 2011) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.